ES2272703T3 - Derivados de piperidina acilados como agonistas de receptor de melanocortina-4. - Google Patents
Derivados de piperidina acilados como agonistas de receptor de melanocortina-4. Download PDFInfo
- Publication number
- ES2272703T3 ES2272703T3 ES02725001T ES02725001T ES2272703T3 ES 2272703 T3 ES2272703 T3 ES 2272703T3 ES 02725001 T ES02725001 T ES 02725001T ES 02725001 T ES02725001 T ES 02725001T ES 2272703 T3 ES2272703 T3 ES 2272703T3
- Authority
- ES
- Spain
- Prior art keywords
- baselineskip
- alkyl
- independently selected
- phenyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 0 CC(C)(CO1)N(CC(CC2)(CCN2C(C(CCN(*)C2)C2c(cc2)ccc2Cl)=O)C2CCCCC2)C1=O Chemical compound CC(C)(CO1)N(CC(CC2)(CCN2C(C(CCN(*)C2)C2c(cc2)ccc2Cl)=O)C2CCCCC2)C1=O 0.000 description 2
- PYRFXZVTSQRNCQ-UHFFFAOYSA-N CC(C)(C)N(CC1C(N(CC2)CCC2(CCC(C)(C)O)C2CCCCC2)=O)CC1c(c(F)c1)ccc1F Chemical compound CC(C)(C)N(CC1C(N(CC2)CCC2(CCC(C)(C)O)C2CCCCC2)=O)CC1c(c(F)c1)ccc1F PYRFXZVTSQRNCQ-UHFFFAOYSA-N 0.000 description 1
- HVHCKXFXUVOMAW-UHFFFAOYSA-N CC(C)(C)N(CCC1C(N(CC2)CCC2(CN(C(C)(C)CO2)C2=O)C2CCCCC2)=O)CC1c(cc1)ccc1Cl Chemical compound CC(C)(C)N(CCC1C(N(CC2)CCC2(CN(C(C)(C)CO2)C2=O)C2CCCCC2)=O)CC1c(cc1)ccc1Cl HVHCKXFXUVOMAW-UHFFFAOYSA-N 0.000 description 1
- CADLMVQVXUHHOM-QXPUDEPPSA-N CC(C)(C)N(CC[C@H]1C(N(CC2)CCC2(CN(C(C)(C)CO2)C2=O)C2CCCCC2)=O)CC1c(cc1)ccc1F Chemical compound CC(C)(C)N(CC[C@H]1C(N(CC2)CCC2(CN(C(C)(C)CO2)C2=O)C2CCCCC2)=O)CC1c(cc1)ccc1F CADLMVQVXUHHOM-QXPUDEPPSA-N 0.000 description 1
- SRRUIQWRRSQQAD-SSYAZFEXSA-N CC(C)(C)N(C[C@H]1C(N(CC2)CCC2(CN(C(C)(C)CO2)C2=O)C2CCCCC2)=O)CC1c(cc1)ccc1F Chemical compound CC(C)(C)N(C[C@H]1C(N(CC2)CCC2(CN(C(C)(C)CO2)C2=O)C2CCCCC2)=O)CC1c(cc1)ccc1F SRRUIQWRRSQQAD-SSYAZFEXSA-N 0.000 description 1
- GDFAUWUHCZAGTD-UHFFFAOYSA-N CC(C)(C)NC(C(CC1)(CCN1C(C(CN(C1)C(C)(C)C)C1c(cc1)ccc1F)=O)C1CCCCC1)=O Chemical compound CC(C)(C)NC(C(CC1)(CCN1C(C(CN(C1)C(C)(C)C)C1c(cc1)ccc1F)=O)C1CCCCC1)=O GDFAUWUHCZAGTD-UHFFFAOYSA-N 0.000 description 1
- SCLCTRAMHCQANN-SSYAZFEXSA-N CC(C)(C)NC(C(CC1)(CCN1[IH]([C@H](CCN(C1)C(C)(C)C)C1c(cc1)ccc1F)=O)C1CCCCC1)=O Chemical compound CC(C)(C)NC(C(CC1)(CCN1[IH]([C@H](CCN(C1)C(C)(C)C)C1c(cc1)ccc1F)=O)C1CCCCC1)=O SCLCTRAMHCQANN-SSYAZFEXSA-N 0.000 description 1
- GAGPEAGIULECIM-UHFFFAOYSA-N CC(C)(CO1)N(CC(CC2)(CCN2C(C(CCN(C2)C(N)=N)C2c(cc2)ccc2Cl)=O)C2CCCCC2)C1=O Chemical compound CC(C)(CO1)N(CC(CC2)(CCN2C(C(CCN(C2)C(N)=N)C2c(cc2)ccc2Cl)=O)C2CCCCC2)C1=O GAGPEAGIULECIM-UHFFFAOYSA-N 0.000 description 1
- HEZQNOYYPJCVMB-UHFFFAOYSA-N CC(C)N(CCC1C(N(CC2)CCC2(CN(C(C)(C)CO2)C2=O)C2CCCCC2)=O)CC1c(cc1)ccc1Cl Chemical compound CC(C)N(CCC1C(N(CC2)CCC2(CN(C(C)(C)CO2)C2=O)C2CCCCC2)=O)CC1c(cc1)ccc1Cl HEZQNOYYPJCVMB-UHFFFAOYSA-N 0.000 description 1
- NUWJLIBEONEXGZ-UHFFFAOYSA-N CCN(CCC1C(N(CC2)CCC2(CN(C(C)(C)CO2)C2=O)C2CCCCC2)=O)CC1c(cc1)ccc1Cl Chemical compound CCN(CCC1C(N(CC2)CCC2(CN(C(C)(C)CO2)C2=O)C2CCCCC2)=O)CC1c(cc1)ccc1Cl NUWJLIBEONEXGZ-UHFFFAOYSA-N 0.000 description 1
- WKBSERNAICYENV-XMMISQBUSA-N CCOC(C(CC1)(CCN1C([C@H](CN(C1)C(C)(C)C)C1c(ccc(F)c1)c1F)=O)C1CCCCC1)=O Chemical compound CCOC(C(CC1)(CCN1C([C@H](CN(C1)C(C)(C)C)C1c(ccc(F)c1)c1F)=O)C1CCCCC1)=O WKBSERNAICYENV-XMMISQBUSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/64—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27225801P | 2001-02-28 | 2001-02-28 | |
| US272258P | 2001-02-28 | ||
| US30057201P | 2001-06-22 | 2001-06-22 | |
| US300572P | 2001-06-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2272703T3 true ES2272703T3 (es) | 2007-05-01 |
Family
ID=26955403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES02725001T Expired - Lifetime ES2272703T3 (es) | 2001-02-28 | 2002-02-25 | Derivados de piperidina acilados como agonistas de receptor de melanocortina-4. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7015235B2 (https=) |
| EP (1) | EP1372653B1 (https=) |
| JP (1) | JP4323169B2 (https=) |
| AT (1) | ATE341327T1 (https=) |
| AU (1) | AU2002255597B8 (https=) |
| CA (1) | CA2439149C (https=) |
| DE (1) | DE60215132T2 (https=) |
| ES (1) | ES2272703T3 (https=) |
| WO (1) | WO2002068387A2 (https=) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7012084B2 (en) | 2001-02-28 | 2006-03-14 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| CA2439152C (en) * | 2001-02-28 | 2008-06-17 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| US6911447B2 (en) | 2001-04-25 | 2005-06-28 | The Procter & Gamble Company | Melanocortin receptor ligands |
| US7115628B2 (en) | 2001-07-18 | 2006-10-03 | Merck & Co., Inc. | Bridged piperidine derivatives as melanocortin receptor agonists |
| US6977264B2 (en) | 2001-07-25 | 2005-12-20 | Amgen Inc. | Substituted piperidines and methods of use |
| US7115607B2 (en) | 2001-07-25 | 2006-10-03 | Amgen Inc. | Substituted piperazinyl amides and methods of use |
| AU2002331064B2 (en) | 2001-08-10 | 2007-08-23 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
| US7354923B2 (en) | 2001-08-10 | 2008-04-08 | Palatin Technologies, Inc. | Piperazine melanocortin-specific compounds |
| US7456184B2 (en) | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
| US7026335B2 (en) | 2002-04-30 | 2006-04-11 | The Procter & Gamble Co. | Melanocortin receptor ligands |
| US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
| WO2004024720A1 (en) | 2002-09-11 | 2004-03-25 | Merck & Co., Inc. | Piperazine urea derivatives as melanocortin-4 receptor agonists |
| TW200504033A (en) | 2002-10-23 | 2005-02-01 | Procter & Gamble | Melanocortin receptor ligands |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| WO2004078717A1 (en) * | 2003-03-03 | 2004-09-16 | Merck & Co., Inc. | Acylated piperazine derivatives as melanocortin-4 receptor agonists |
| US6998488B2 (en) | 2003-03-10 | 2006-02-14 | Merck & Co., Inc. | Process and intermediates for the preparation of 4-aryl piperidines |
| CN1764458A (zh) | 2003-03-26 | 2006-04-26 | 麦克公司 | 作为黑皮质素－4受体激动剂的双环哌啶衍生物 |
| CN1768041A (zh) | 2003-04-04 | 2006-05-03 | 麦克公司 | 作为黑皮质素－4受体激动剂的酰化螺哌啶衍生物 |
| AR044510A1 (es) * | 2003-04-14 | 2005-09-14 | Merck & Co Inc | Procedimiento e intermedios para preparar acidos carboxilicos de pirrolidina |
| US7049323B2 (en) | 2003-04-25 | 2006-05-23 | Bristol-Myers Squibb Company | Amidoheterocycles as modulators of the melanocortin-4 receptor |
| WO2005009950A2 (en) | 2003-07-22 | 2005-02-03 | Merck & Co., Inc. | Piperidine derivatives as melanocortin-4 receptor agonists |
| ATE547404T1 (de) | 2003-09-22 | 2012-03-15 | Msd Kk | Piperidinderivate |
| GB0402492D0 (en) * | 2004-02-04 | 2004-03-10 | Pfizer Ltd | Pharmaceutically active compounds |
| US7649002B2 (en) | 2004-02-04 | 2010-01-19 | Pfizer Inc | (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists |
| JP5111101B2 (ja) * | 2004-03-02 | 2012-12-26 | 株式会社ブリヂストン | バルク重合プロセス |
| EP1734963A4 (en) | 2004-04-02 | 2008-06-18 | Merck & Co Inc | METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER |
| JP2008506779A (ja) | 2004-07-19 | 2008-03-06 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン−４受容体作用薬としてのアシル化ピペリジン誘導体 |
| CN101094689B (zh) | 2004-11-01 | 2013-06-12 | 安米林药品有限责任公司 | 治疗肥胖以及肥胖相关疾病和病症的方法 |
| GB0428514D0 (en) * | 2004-12-31 | 2005-02-09 | Prosidion Ltd | Compounds |
| WO2007022123A2 (en) | 2005-08-11 | 2007-02-22 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
| BRPI0610580B8 (pt) | 2005-05-30 | 2021-05-25 | Banyu Pharma Co Ltd | composto derivado de piperidina |
| US20070021433A1 (en) | 2005-06-03 | 2007-01-25 | Jian-Qiang Fan | Pharmacological chaperones for treating obesity |
| AU2006275702A1 (en) | 2005-07-29 | 2007-02-08 | Concert Pharmaceuticals Inc. | Novel pharmaceutical compounds |
| CA2617654A1 (en) * | 2005-08-04 | 2007-02-08 | Pfizer Limited | Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds |
| JPWO2007018248A1 (ja) | 2005-08-10 | 2009-02-19 | 萬有製薬株式会社 | ピリドン化合物 |
| EP2330125A3 (en) | 2005-08-11 | 2012-12-12 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
| WO2007024004A1 (ja) | 2005-08-24 | 2007-03-01 | Banyu Pharmaceutical Co., Ltd. | フェニルピリドン誘導体 |
| WO2007029847A1 (ja) | 2005-09-07 | 2007-03-15 | Banyu Pharmaceutical Co., Ltd. | 二環性芳香族置換ピリドン誘導体 |
| EP1940842B1 (en) * | 2005-09-29 | 2012-05-30 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| AU2006304305B2 (en) | 2005-10-18 | 2010-04-01 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| JP2009512715A (ja) | 2005-10-21 | 2009-03-26 | ノバルティス アクチエンゲゼルシャフト | レニン阻害剤と抗異脂肪血症剤および／または抗肥満症剤の組み合わせ |
| EP1944301A4 (en) | 2005-10-27 | 2012-01-04 | Msd Kk | NEW BENZOXATHIIN DERIVATIVES |
| ES2381205T3 (es) | 2005-11-10 | 2012-05-24 | Msd K.K. | Derivado espiro aza-sustituido |
| WO2007096763A2 (en) | 2006-02-23 | 2007-08-30 | Pfizer Limited | Melanocortin type 4 receptor agonist piperidinoylpyrrolidines |
| CN101426782B (zh) * | 2006-02-23 | 2012-10-31 | 辉瑞股份有限公司 | 黑皮质素4型受体激动剂哌啶羰基吡咯烷 |
| US8173629B2 (en) | 2006-09-22 | 2012-05-08 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| US20090247560A1 (en) | 2006-09-28 | 2009-10-01 | Banyu Pharmaceutical Co., Ltd. | Diaryl ketimine derivative |
| JP5319518B2 (ja) | 2007-04-02 | 2013-10-16 | Ｍｓｄ株式会社 | インドールジオン誘導体 |
| MX354786B (es) | 2007-06-04 | 2018-03-21 | Synergy Pharmaceuticals Inc | Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos. |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| JP2010540629A (ja) * | 2007-10-04 | 2010-12-24 | メルク・シャープ・エンド・ドーム・コーポレイション | カルシウムチャネル遮断薬としての置換アリールスルホン誘導体 |
| EP2264026A4 (en) | 2008-03-06 | 2012-03-28 | Msd Kk | ALKYLAMINOPYRIDINDERIVATE |
| WO2009119726A1 (ja) | 2008-03-28 | 2009-10-01 | 萬有製薬株式会社 | メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体 |
| ES2522968T3 (es) | 2008-06-04 | 2014-11-19 | Synergy Pharmaceuticals Inc. | Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
| JPWO2009154132A1 (ja) | 2008-06-19 | 2011-12-01 | Ｍｓｄ株式会社 | スピロジアミン−ジアリールケトオキシム誘導体 |
| AU2009270833B2 (en) | 2008-07-16 | 2015-02-19 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| EP2319841A1 (en) | 2008-07-30 | 2011-05-11 | Msd K.K. | (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative |
| KR101280786B1 (ko) | 2008-08-06 | 2013-07-05 | 화이자 리미티드 | 멜라노코르틴 4 작용제로서 다이아제핀 및 다이아조칸 화합물 |
| EP2348857B1 (en) | 2008-10-22 | 2016-02-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| US8329914B2 (en) | 2008-10-31 | 2012-12-11 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| UA99555C2 (en) | 2008-11-12 | 2012-08-27 | Элджи Лайф Саенсез Лтд. | Melanocortin receptor agonists |
| EP2358200A4 (en) | 2008-11-17 | 2012-05-16 | Merck Sharp & Dohme | SUBSTITUTED BICYCLIC AMINES FOR THE TREATMENT OF DIABETES |
| CN102245570A (zh) * | 2008-12-16 | 2011-11-16 | 弗·哈夫曼-拉罗切有限公司 | 制备吡咯烷-3-甲酸类的方法 |
| US8324250B2 (en) * | 2009-03-19 | 2012-12-04 | Hoffmann-La Roche Inc. | Piperidine derivatives as NK3 receptor antagonists |
| WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| CA2768577A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| US8476227B2 (en) | 2010-01-22 | 2013-07-02 | Ethicon Endo-Surgery, Inc. | Methods of activating a melanocortin-4 receptor pathway in obese subjects |
| US9044606B2 (en) | 2010-01-22 | 2015-06-02 | Ethicon Endo-Surgery, Inc. | Methods and devices for activating brown adipose tissue using electrical energy |
| JP2013520502A (ja) | 2010-02-25 | 2013-06-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体 |
| WO2011137024A1 (en) | 2010-04-26 | 2011-11-03 | Merck Sharp & Dohme Corp. | Novel spiropiperidine prolylcarboxypeptidase inhibitors |
| EP2563127A4 (en) | 2010-04-27 | 2013-11-06 | Merck Sharp & Dohme | PROLYLCARBOXYPEPTIDASE INHIBITORS |
| EP2568812B1 (en) | 2010-05-11 | 2016-10-26 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
| WO2011156246A1 (en) | 2010-06-11 | 2011-12-15 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| WO2012100342A1 (en) | 2011-01-27 | 2012-08-02 | Université de Montréal | Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators |
| SG192941A1 (en) | 2011-02-25 | 2013-09-30 | Merck Sharp & Dohme | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| RU2015106909A (ru) | 2012-08-02 | 2016-09-27 | Мерк Шарп И Доум Корп. | Антидиабетические трициклические соединения |
| KR20150118158A (ko) | 2013-02-22 | 2015-10-21 | 머크 샤프 앤드 돔 코포레이션 | 항당뇨병 비시클릭 화합물 |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
| AU2014235215A1 (en) | 2013-03-15 | 2015-10-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| BR112015030326A2 (pt) | 2013-06-05 | 2017-08-29 | Synergy Pharmaceuticals Inc | Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| KR102431436B1 (ko) | 2014-08-29 | 2022-08-10 | 테스 파마 에스.알.엘. | α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제 |
| US10080884B2 (en) | 2014-12-29 | 2018-09-25 | Ethicon Llc | Methods and devices for activating brown adipose tissue using electrical energy |
| US10092738B2 (en) | 2014-12-29 | 2018-10-09 | Ethicon Llc | Methods and devices for inhibiting nerves when activating brown adipose tissue |
| WO2018069532A1 (en) | 2016-10-14 | 2018-04-19 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| EP3558298B1 (en) | 2016-12-20 | 2026-03-11 | Merck Sharp & Dohme LLC | Antidiabetic spirochroman compounds |
| AR117122A1 (es) | 2018-11-20 | 2021-07-14 | Tes Pharma S R L | INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994022460A1 (en) * | 1993-04-05 | 1994-10-13 | University Patents, Inc. | Diagnosis and treatment of erectile dysfunction |
| US6166037A (en) * | 1997-08-28 | 2000-12-26 | Merck & Co., Inc. | Pyrrolidine and piperidine modulators of chemokine receptor activity |
| EP1009405A4 (en) | 1997-08-28 | 2001-05-09 | Merck & Co Inc | PAYRROLIDINE AND PIPERIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY |
| CA2377369A1 (en) * | 1999-06-04 | 2000-12-14 | Merck & Co., Inc. | Substituted piperidines as melanocortin-4 receptor agonists |
| HUP0301391A3 (en) | 2000-02-11 | 2010-03-29 | Vertex Pharma | Piperazine and piperidine derivatives pharmaceutical compositions containing them and their use |
| WO2001070708A1 (en) * | 2000-03-23 | 2001-09-27 | Merck & Co., Inc. | Substituted piperidines as melanocortin receptor agonists |
| JP2003534377A (ja) * | 2000-05-30 | 2003-11-18 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン受容体作働薬 |
| US6511994B2 (en) * | 2000-10-11 | 2003-01-28 | Merck & Co., Inc. | Modulators of CCR5 chemokine receptor activity |
| CA2439152C (en) * | 2001-02-28 | 2008-06-17 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| US7012084B2 (en) | 2001-02-28 | 2006-03-14 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
-
2002
- 2002-02-25 DE DE60215132T patent/DE60215132T2/de not_active Expired - Lifetime
- 2002-02-25 CA CA2439149A patent/CA2439149C/en not_active Expired - Fee Related
- 2002-02-25 EP EP02725001A patent/EP1372653B1/en not_active Expired - Lifetime
- 2002-02-25 JP JP2002567901A patent/JP4323169B2/ja not_active Expired - Fee Related
- 2002-02-25 ES ES02725001T patent/ES2272703T3/es not_active Expired - Lifetime
- 2002-02-25 WO PCT/US2002/005623 patent/WO2002068387A2/en not_active Ceased
- 2002-02-25 AT AT02725001T patent/ATE341327T1/de not_active IP Right Cessation
- 2002-02-25 AU AU2002255597A patent/AU2002255597B8/en not_active Ceased
- 2002-02-25 US US10/468,515 patent/US7015235B2/en not_active Expired - Lifetime
-
2005
- 2005-09-30 US US11/239,721 patent/US20060035935A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002068387A8 (en) | 2003-09-04 |
| CA2439149C (en) | 2012-04-24 |
| DE60215132T2 (de) | 2007-08-23 |
| JP2004527498A (ja) | 2004-09-09 |
| AU2002255597B2 (en) | 2006-03-02 |
| WO2002068387A2 (en) | 2002-09-06 |
| CA2439149A1 (en) | 2002-09-06 |
| EP1372653A4 (en) | 2005-10-05 |
| JP4323169B2 (ja) | 2009-09-02 |
| US20060035935A1 (en) | 2006-02-16 |
| EP1372653A2 (en) | 2004-01-02 |
| AU2002255597B8 (en) | 2006-10-26 |
| US7015235B2 (en) | 2006-03-21 |
| DE60215132D1 (de) | 2006-11-16 |
| WO2002068387A3 (en) | 2003-02-20 |
| ATE341327T1 (de) | 2006-10-15 |
| EP1372653B1 (en) | 2006-10-04 |
| US20040097546A1 (en) | 2004-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2272703T3 (es) | Derivados de piperidina acilados como agonistas de receptor de melanocortina-4. | |
| ES2283550T3 (es) | Derivados de piperidina acilados como antagonistas del receptor de. | |
| US7700778B2 (en) | Acylated piperidine derivatives as melanocortin-4 receptor agonists | |
| US6767915B2 (en) | Substituted piperidines as melanocortin receptor agonists | |
| AU2002320494B2 (en) | Bridged piperidine derivatives as melanocortin receptor agonists | |
| AU2002255597A1 (en) | Acylated piperidine derivatives as melanocortin-4 receptor agonists | |
| AU5306800A (en) | Substituted piperidines as melanocortin-4 receptor agonists | |
| AU2002250343A1 (en) | Acylated piperidine derivatives as melanocortin-4 receptor agonists | |
| AU2002258414A1 (en) | Acylated Piperidine Derivatives as Melanocortin-4 Receptor Agonists | |
| US20040266821A1 (en) | Acylated piperidine derivatives as melanocortin-4 receptor agonists |